Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.66
-$0.14(-7.65%)
At close: 4:00 PM EST
$1.66
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$1.53 - $4.95
Previous CloseN/A
Volume58.77K
Average Volume (3M)1.34M
Market Cap
$543.71M
Enterprise Value$490.33M
Total Cash (Recent Filing)$224.94M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding205,199,700
10 Day Avg. Volume2,217,539
30 Day Avg. Volume1,340,962
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue551.55
Enterprise Value/Gross Profit-245.78
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$5.75Price Target Upside246.39% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$511.14K
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment (FDA EGFR Surrogate)FDA agreement on using eGFR slope as a surrogate endpoint materially strengthens ProKidney's development pathway. This alignment reduces regulatory uncertainty, enables potential accelerated approval, and meaningfully shortens time-to-market conditional on positive Phase 3 results, improving the strategic odds for commercialization.
Sufficient Near-term LiquidityA cash position near $225M that management expects to fund operations into mid-2027 provides durable support to complete pivotal PROACT 1 activities and topline readout. This runway lowers immediate refinancing pressure, allowing focused investment in clinical and manufacturing execution over the next 12–18 months.
Low Financial LeverageVery low absolute debt reduces insolvency and interest-service risk for a pre-revenue biotech. Low leverage preserves flexibility to raise capital via equity or partnerships without heavy fixed obligations, supporting continued R&D investment and protecting operational continuity during the pivotal trial period.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow implies recurring financing needs beyond current runway if timelines slip. High burn magnifies dilution risk or dependence on partnerships, constrains optionality for pipeline expansion, and places persistent pressure on management to secure capital before commercialization.
Minimal, Declining RevenueWith essentially no product revenue and a sharp revenue decline, the company remains fully reliant on external financing and non-recurring income. This lack of commercialization validation and operating cash inflows elevates execution risk and limits the firm's ability to internally fund scaling or absorb adverse trial outcomes.
Large, Persistent Operating LossesDeep, ongoing operating losses reflect the high fixed cost of pivotal trials and manufacturing scale-up. Without regulatory success and commercialization, these losses are structurally unsustainable, likely forcing dilution or strategic transactions and meaningfully extending the path to profitability absent transformative clinical outcomes.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $1.53 and its highest was $4.95 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $543.71M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on May 15, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.14.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 205,199,700 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -2.924%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (246.39% Upside)
$5.75 (246.39% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 54.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.02%
12-Months-Change
Fundamentals
Return on Equity
7.40%
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.75
▲(246.39% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
49.16% Insiders
1.99% Mutual Funds
0.91% Other Institutional Investors
45.66% Public Companies and
Individual Investors